About 23 jobs are gone as Aura Biosciences narrows its focus to a single eye cancer drug and stretches cash into 2029.

LifeMine Therapeutics just banked $263 million for a kidney-friendly transplant drug — a comeback for a scientist whose first startup nearly went nowhere.

Boston’s Liquid AI is betting a leaner model architecture can challenge OpenAI and Anthropic. A $250 million AMD-led round is helping fund the fight.

Analog Devices disclosed unauthorized access to company systems after files were stolen. The Wilmington chipmaker has not said what data was taken or whether customers were affected.

Commonwealth Fusion Systems has raised another $1 billion, bringing its total capital to $4 billion as SPARC construction advances in Devens.

Marlborough‑based Boston Scientific approved a global restructuring this week with $700–$800M in charges and plans to shift production — and some jobs — as it refocuses resources. The company says much of the savings will be reinvested in growth areas.

argenx agreed to buy Dallas‑based Forte for about $2.2 billion, folding Forte’s experimental anti‑CD122 drug FB102 into argenx’s immunology lineup.

Boston‑based Salsify has agreed to be acquired by Cinven on July 22, 2026. Terms were not disclosed; the company says it will pursue product and international growth under new ownership.

A Broad‑led nonprofit with Boston Children’s and Jackson Laboratory aims to make personalized gene‑editing treatments repeatable and more affordable for rare disease patients.

Former SentinelOne exec Nick Warner has launched Neo with $100M to build a control layer for agentic AI, backed by a16z and Bessemer.

Leaked Suno source code appears to document millions of scraped tracks and a customer list; affected users say they were not told after a November 2025 breach.

MGH and Dana‑Farber researchers built Aladynoulli, an AI trained on about 683,000 records that estimates risk for 348 conditions and could be tested inside hospital EHRs.

A Cambridge startup spun out of Toyota research revealed a $300M raise and a $1.1B valuation as it pushes humanoid machines into factory work.